Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is a promising cancer immunotherapy, particularly effective against hematological malignancies.
• CAR-T therapy faces significant challenges in treating solid tumors due to the immunosuppressive tumor microenvironment.
• Current preclinical models often fail to accurately predict CAR-T therapy's efficacy and adverse effects like cytokine release syndrome and neurotoxicity.

Purpose of the Study:

• To evaluate the effectiveness and limitations of various preclinical animal models used in CAR-T therapy research.
• To highlight the challenges associated with CAR-T therapy in solid tumors and potential side effects.
• To emphasize the critical need for careful selection of appropriate preclinical models for advancing CAR-T therapy.

Main Methods:

• Review of existing literature on CAR-T therapy preclinical studies, primarily in mouse models (syngeneic, xenograft, transgenic, humanized).
• Inclusion of recent studies utilizing primate models to better mimic clinical side effects.
• Analysis of model limitations in recapitulating the human immune system and tumor microenvironment.

Main Results:

• Mouse models frequently overestimate CAR-T efficacy and do not reliably predict adverse events.
• Primate models show potential for better prediction of clinical side effects.
• No single preclinical model perfectly replicates human conditions, and model selection can lead to contradictory findings.

Conclusions:

• Preclinical model selection is a critical factor in accurately evaluating CAR-T treatment efficacy and safety.
• Advancements in preclinical modeling are essential for the development of safer and more effective CAR-T therapies.
• Addressing limitations in current models is key to overcoming challenges in CAR-T treatment for solid tumors.